Abstract:Parkinson's disease (PD) is among the most prevalent neurodegenerative disorders, affecting over 10 million people worldwide. The protein encoded by the SNCA gene, alpha‐synuclein (ASYN), is the major component of Lewy body (LB) aggregates, a histopathological hallmark of PD. Mutations and posttranslational modifications (PTMs) in ASYN are known to influence protein aggregation and LB formation, possibly playing a crucial role in PD pathogenesis. In this work, we applied computational methods to characterize the effects of missense mutations and PTMs on the structure and function of ASYN. Missense mutations in ASYN were compiled from the literature/databases and underwent a comprehensive predictive analysis. Phosphorylation and SUMOylation sites of ASYN were retrieved from databases and predicted by algorithms. ConSurf was used to estimate the evolutionary conservation of ASYN amino acids. Molecular dynamics (MD) simulations of ASYN wild‐type and variants A30G, A30P, A53T, and G51D were performed using the GROMACS package. Seventy‐seven missense mutations in ASYN were compiled. Although most mutations were not predicted to affect ASYN stability, aggregation propensity, amyloid formation, and chaperone binding, the analyzed mutations received relatively high rates of deleterious predictions and predominantly occurred at evolutionarily conserved sites within the protein. Moreover, our predictive analyses suggested that the following mutations may be possibly harmful to ASYN and, consequently, potential targets for future investigation: K6N, T22I, K34E, G36R, G36S, V37F, L38P, G41D, and K102E. The MD analyses pointed to remarkable flexibility and essential dynamics alterations at nearly all domains of the studied variants, which could lead to impaired contact between NAC and the C‐terminal domain triggering protein aggregation. These alterations may have functional implications for ASYN and provide important insight into the molecular mechanism of PD, supporting the design of future biomedical research and improvements in existing therapies for the disease.

The phosphorylation of α‐synuclein: development and implication for the mechanism and therapy of the Parkinson's disease

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

Effect of Ser-129 Phosphorylation on Interaction of Α-Synuclein with Synaptic and Cellular Membranes.

Exploring the role of post‐translational modifications in regulating α‐synuclein interactions by studying the effects of phosphorylation on nanobody binding

alpha-Synuclein as a Diagnostic Marker and Therapeutic Target for Parkinson Disease

α-Synuclein as a Diagnostic Marker and Therapeutic Target for Parkinson Disease

Physiological and Pathological Functions of Neuronal Hemoglobin: A Key Underappreciated Protein in Parkinson’s Disease

Navigating the Neurobiology of Parkinson's: The Impact and Potential of α-Synuclein

The Role of α-Synuclein Oligomers in Parkinson’s Disease

Small Molecules, α-Synuclein Pathology, and the Search for Effective Treatments in Parkinson's Disease

[Alpha-synuclein interacted proteins: the relevance with the pathogenesis of Parkinson's disease].

Protein–protein interactions regulating α-synuclein pathology

Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified Α-Synuclein.

Leucine Carboxyl Methyltransferase Downregulation and Protein Phosphatase Methylesterase Upregulation Contribute Toward the Inhibition of Protein Phosphatase 2A by α-Synuclein

Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies

alpha-synuclein, autophagy-lysosomal pathway, and Lewy bodies: mutations, propagation, aggregation, and the formation of inclusions

Biomarkers and the Role of α-Synuclein in Parkinson’s Disease

Initiation and propagation of α-synuclein aggregation in the nervous system

Alpha-Synuclein Aggregation in Parkinson's Disease

In silico analysis of alpha‐synuclein protein variants and posttranslational modifications related to Parkinson's disease

1 serine 129 phosphorylation reduces α-synuclein ’ s ability to regulate tyrosine hydroxylase and protein phosphatase 2 a in vitro and in vivo